RADX
Radiopharm Theranostics Limited
There isn't enough reported data to score RADX yet.
RADX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
RADX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
RADX PE Valuation
RADX has no meaningful PE right now: it lost money over the past year.
RADX Forward outlook
There aren't enough analyst estimates for RADX to show an outlook.
RADX Earnings Per Share
RADX Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -1051% | N/A |
RADX Free Cash Flow
RADX Total Shares
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
RADX Net Leverage
RADX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RADX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 16.5 | Oversold |
| Stochastic | 4.7 | Oversold |
RADX's weekly RSI is 16 (oversold) and its Stochastic is 5 (oversold).
RADX PE vs Healthcare Sector
RADX has no meaningful PE right now: it lost money over the past year.
RADX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.13 | 30% below |
| 20 week MA | $2.24 | 65% below |
| 50 week MA | $3.72 | 79% below |
| 100 week MA | $4.38 | 82% below |
RADX is in a downtrend: it's below all four of its weekly moving averages, and 82% below its 100-week average.
RADX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $18.9 | $4.67 | -75% |
| 2025 | $4.67 | $5.50 | +18% |
| 2026 YTD | $5.50 | $0.79 | -86% |
RADX has finished lower in one of the last two years. It's down 86% so far in 2026.